213 related articles for article (PubMed ID: 23261716)
1. New enzymatic assay for the AKR1C enzymes.
Beranič N; Stefane B; Brus B; Gobec S; Rižner TL
Chem Biol Interact; 2013 Feb; 202(1-3):204-9. PubMed ID: 23261716
[TBL] [Abstract][Full Text] [Related]
2. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
Beranič N; Gobec S; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
[TBL] [Abstract][Full Text] [Related]
3. Ruthenium complexes as inhibitors of the aldo-keto reductases AKR1C1-1C3.
Traven K; Sinreih M; Stojan J; Seršen S; Kljun J; Bezenšek J; Stanovnik B; Turel I; Rižner TL
Chem Biol Interact; 2015 Jun; 234():349-59. PubMed ID: 25446855
[TBL] [Abstract][Full Text] [Related]
4. Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily.
Ruiz FX; Porté S; Gallego O; Moro A; Ardèvol A; Del Río-Espínola A; Rovira C; Farrés J; Parés X
Biochem J; 2011 Dec; 440(3):335-44. PubMed ID: 21851338
[TBL] [Abstract][Full Text] [Related]
5. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
Stefane B; Brozic P; Vehovc M; Rizner TL; Gobec S
Eur J Med Chem; 2009 Jun; 44(6):2563-71. PubMed ID: 19237229
[TBL] [Abstract][Full Text] [Related]
6. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Byrns MC; Steckelbroeck S; Penning TM
Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
[TBL] [Abstract][Full Text] [Related]
7. Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Khanim F; Davies N; Veliça P; Hayden R; Ride J; Pararasa C; Chong MG; Gunther U; Veerapen N; Winn P; Farmer R; Trivier E; Rigoreau L; Drayson M; Bunce C
Br J Cancer; 2014 Mar; 110(6):1506-16. PubMed ID: 24569460
[TBL] [Abstract][Full Text] [Related]
8. 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Gazvoda M; Beranič N; Turk S; Burja B; Kočevar M; Rižner TL; Gobec S; Polanc S
Eur J Med Chem; 2013 Apr; 62():89-97. PubMed ID: 23353746
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library.
Brožič P; Turk S; Adeniji AO; Konc J; Janežič D; Penning TM; Lanišnik Rižner T; Gobec S
J Med Chem; 2012 Sep; 55(17):7417-24. PubMed ID: 22881866
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of the synthetic progestogen norethynodrel by human ketosteroid reductases of the aldo-keto reductase superfamily.
Jin Y; Duan L; Chen M; Penning TM; Kloosterboer HJ
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):139-44. PubMed ID: 22210085
[TBL] [Abstract][Full Text] [Related]
11. N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
Sinreih M; Sosič I; Beranič N; Turk S; Adeniji AO; Penning TM; Rižner TL; Gobec S
Bioorg Med Chem Lett; 2012 Sep; 22(18):5948-51. PubMed ID: 22897946
[TBL] [Abstract][Full Text] [Related]
12. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Byrns MC; Penning TM
Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
[TBL] [Abstract][Full Text] [Related]
13. Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line.
Beranič N; Lanišnik Rižner T
Chem Biol Interact; 2013 Feb; 202(1-3):218-25. PubMed ID: 23183084
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.
Byrns MC; Jin Y; Penning TM
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):95-104. PubMed ID: 21087665
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence studies of tibolone in premenopausal women and effects on expression of the tibolone-metabolizing enzyme AKR1C (aldo-keto reductase) family caused by estradiol.
Kang KW; Kim YG
J Clin Pharmacol; 2008 Dec; 48(12):1430-7. PubMed ID: 18832293
[TBL] [Abstract][Full Text] [Related]
16. Retention of NADPH-linked quinone reductase activity in an aldo-keto reductase following mutation of the catalytic tyrosine.
Schlegel BP; Ratnam K; Penning TM
Biochemistry; 1998 Aug; 37(31):11003-11. PubMed ID: 9692994
[TBL] [Abstract][Full Text] [Related]
17. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.
Wsol V; Szotakova B; Martin HJ; Maser E
Toxicology; 2007 Sep; 238(2-3):111-8. PubMed ID: 17618725
[TBL] [Abstract][Full Text] [Related]
18. Mutagenesis of 3 alpha-hydroxysteroid dehydrogenase reveals a "push-pull" mechanism for proton transfer in aldo-keto reductases.
Schlegel BP; Jez JM; Penning TM
Biochemistry; 1998 Mar; 37(10):3538-48. PubMed ID: 9521675
[TBL] [Abstract][Full Text] [Related]
19. Stereospecific reduction of 5β-reduced steroids by human ketosteroid reductases of the AKR (aldo-keto reductase) superfamily: role of AKR1C1-AKR1C4 in the metabolism of testosterone and progesterone via the 5β-reductase pathway.
Jin Y; Mesaros AC; Blair IA; Penning TM
Biochem J; 2011 Jul; 437(1):53-61. PubMed ID: 21521174
[TBL] [Abstract][Full Text] [Related]
20. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]